Geographic Disparities in Stroke Outcomes and Service Access: A Prospective Observational Study.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
27 May 2022
27 May 2022
Historique:
received:
19
09
2021
accepted:
01
03
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
28
5
2022
Statut:
aheadofprint
Résumé
International evidence shows that patients treated at non-urban hospitals experience poorer access to key stroke interventions. Evidence whether this results in poorer outcomes is conflicting and generally based on administrative or voluntary registry data. The aim of this study was to use prospective high-quality comprehensive nationwide patient level data to investigate the association between hospital geography and stroke patient outcomes and access to best practice stroke care in New Zealand. This is a prospective, multi-centre, nationally representative observational study involving all 28 New Zealand acute stroke hospitals (18 non-urban), and affiliated rehabilitation and community services. Consecutive adults admitted to the hospital with acute stroke between 1 May and 31 October 2018 were captured. Outcomes included functional outcome (modified Rankin Scale (mRS) shift analysis), functional independence (mRS scores 0-2), quality of life (EQ5D-3L), stroke/vascular events, and death at 3, 6, and 12 months and proportion accessing thrombolysis, thrombectomy, stroke units, key investigations, secondary prevention, and inpatient/community rehabilitation. Results were adjusted for age, sex, ethnicity, stroke severity/type, co-morbidities, baseline function, and differences in baseline characteristics. Overall, 2,379 patients were eligible (mean (standard deviation) age 75 (13.7); 51.2% male; 1,430 urban; 949 non-urban). Patients treated at non-urban hospitals were more likely to score in a higher mRS category (greater disability) at three (aOR=1.28, 1.07-1.53), six (aOR=1.33, 1.07-1.65) and twelve months (aOR=1.31, 1.06-1.62) and were more likely to have died (aOR=1.57, 1.17-2.12) or experienced recurrent stroke and vascular events at 12 months (aOR=1.94, 1.14-3.29 and aOR=1.65, 1.09-2.52). Fewer non-urban patients received recommended stroke interventions including endovascular thrombectomy (aOR=0.25, 95% confidence interval 0.13-0.49), acute stroke unit care (aOR=0.60, 0.49-0.73), antiplatelet prescriptions (aOR=0.72, 0.58-0.88), ≥60 minutes daily physical therapy (aOR=0.55, 0.40-0.77) and community rehabilitation (aOR=0.69, 0.56-0.84). Patients managed at non-urban hospitals experience poorer stroke outcomes and reduced access to key stroke interventions across the entire care continuum. Efforts to improve access to high quality stroke care in non-urban hospitals should be a priority.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
International evidence shows that patients treated at non-urban hospitals experience poorer access to key stroke interventions. Evidence whether this results in poorer outcomes is conflicting and generally based on administrative or voluntary registry data. The aim of this study was to use prospective high-quality comprehensive nationwide patient level data to investigate the association between hospital geography and stroke patient outcomes and access to best practice stroke care in New Zealand.
METHODS
METHODS
This is a prospective, multi-centre, nationally representative observational study involving all 28 New Zealand acute stroke hospitals (18 non-urban), and affiliated rehabilitation and community services. Consecutive adults admitted to the hospital with acute stroke between 1 May and 31 October 2018 were captured. Outcomes included functional outcome (modified Rankin Scale (mRS) shift analysis), functional independence (mRS scores 0-2), quality of life (EQ5D-3L), stroke/vascular events, and death at 3, 6, and 12 months and proportion accessing thrombolysis, thrombectomy, stroke units, key investigations, secondary prevention, and inpatient/community rehabilitation. Results were adjusted for age, sex, ethnicity, stroke severity/type, co-morbidities, baseline function, and differences in baseline characteristics.
RESULTS
RESULTS
Overall, 2,379 patients were eligible (mean (standard deviation) age 75 (13.7); 51.2% male; 1,430 urban; 949 non-urban). Patients treated at non-urban hospitals were more likely to score in a higher mRS category (greater disability) at three (aOR=1.28, 1.07-1.53), six (aOR=1.33, 1.07-1.65) and twelve months (aOR=1.31, 1.06-1.62) and were more likely to have died (aOR=1.57, 1.17-2.12) or experienced recurrent stroke and vascular events at 12 months (aOR=1.94, 1.14-3.29 and aOR=1.65, 1.09-2.52). Fewer non-urban patients received recommended stroke interventions including endovascular thrombectomy (aOR=0.25, 95% confidence interval 0.13-0.49), acute stroke unit care (aOR=0.60, 0.49-0.73), antiplatelet prescriptions (aOR=0.72, 0.58-0.88), ≥60 minutes daily physical therapy (aOR=0.55, 0.40-0.77) and community rehabilitation (aOR=0.69, 0.56-0.84).
DISCUSSION
CONCLUSIONS
Patients managed at non-urban hospitals experience poorer stroke outcomes and reduced access to key stroke interventions across the entire care continuum. Efforts to improve access to high quality stroke care in non-urban hospitals should be a priority.
Identifiants
pubmed: 35623890
pii: WNL.0000000000200526
doi: 10.1212/WNL.0000000000200526
pmc: PMC9421775
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022 American Academy of Neurology.
Références
Neurocrit Care. 2020 Jun;32(3):715-724
pubmed: 32232726
PLoS One. 2015 Aug 20;10(8):e0134609
pubmed: 26291829
BMJ. 2019 Jan 23;364:l1
pubmed: 30674465
Disabil Rehabil. 2012;34(25):2132-8
pubmed: 22524794
Stroke. 2020 Jul;51(7):2131-2138
pubmed: 32833593
BMJ Open. 2021 Apr 1;11(4):e040418
pubmed: 33795291
Intern Med J. 2020 Nov;50(11):1367-1372
pubmed: 31707750
J Rural Health. 2011 Winter;27(4):401-8
pubmed: 21967384
JMIR Res Protoc. 2021 Jan 12;10(1):e25374
pubmed: 33433396
Cochrane Database Syst Rev. 2013 Sep 11;(9):CD000197
pubmed: 24026639
Intern Med J. 2017 Nov;47(11):1270-1275
pubmed: 28742223
BMJ. 2014 Aug 05;349:g4757
pubmed: 25098169
N Z Med J. 2014 Sep 12;127(1402):10-9
pubmed: 25228417
J Neurol Sci. 2016 Apr 15;363:16-20
pubmed: 27000213
Neurology. 2017 Jan 31;88(5):441-448
pubmed: 28053009
Lancet Neurol. 2006 Feb;5(2):130-9
pubmed: 16426989
J Rural Health. 2012 Summer;28(3):242-7
pubmed: 22757948
N Z Med J. 2012 Jul 29;125(1358):44-51
pubmed: 22864156
J Rural Health. 2014 Winter;30(1):1-6
pubmed: 24383479
Lancet. 2009 Jul 4;374(9683):76-85
pubmed: 19577696
Lancet Reg Health West Pac. 2022 Jan 03;20:100358
pubmed: 35036976
Lancet Neurol. 2019 May;18(5):439-458
pubmed: 30871944
Lancet. 2019 Nov 2;394(10209):1613-1614
pubmed: 31690438